Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Bihar, a state in eastern India, is known for its many rivers that flow across…
Uttar Pradesh is a state in northern India known for its rich history, cultural diversity…
Parliament has cleared the Sustainable Harnessing and Advancement of Nuclear Energy for Transforming India (SHANTI)…
Brazil officially transferred the BRICS presidency to India on December 12, 2025, during the concluding…
Uttarakhand, a beautiful state in northern India, is known for its scenic mountains, holy rivers…
India is rich in natural resources, with different states known for producing specific minerals. Some…